Literature DB >> 3997734

Pulmonary vasodilator responses to vasoactive intestinal peptide in the cat.

P A Nandiwada, P J Kadowitz, S I Said, M Mojarad, A L Hyman.   

Abstract

We investigated the effects of vasoactive intestinal peptide (VIP) in the feline pulmonary vascular bed under conditions of controlled pulmonary blood flow when pulmonary vascular tone was at base-line levels and when vascular resistance was elevated. Under base-line conditions, VIP caused small but significant reductions in lobar arterial pressure without affecting left atrial pressure. Decreases in lobar arterial pressure in response to VIP were greater and were dose related when lobar vascular resistance was increased by intralobar infusion of U 46619, a stable prostaglandin endoperoxide analogue. Acetylcholine and isoproterenol also caused significant decreases in lobar arterial pressure under base-line conditions, and responses to these agents were enhanced when lobar vascular tone was elevated. Moreover, when doses of these agents are expressed in nanomoles, acetylcholine and isoproterenol were more potent than VIP in decreasing lobar arterial pressure. Responses to VIP were longer in duration with a slower onset than were responses to acetylcholine or isoproterenol. Pulmonary vasodilator responses to VIP were unchanged by indomethacin, atropine, or propranolol. The present data demonstrate that VIP has vasodilator activity in the pulmonary vascular bed and that responses are dependent on the existing level of vasoconstrictor tone. These studies indicate that this peptide is less potent than acetylcholine or isoproterenol in dilating the feline pulmonary vascular bed and that responses to VIP are not dependent on a muscarinic or beta-adrenergic mechanism or release of a dilator prostaglandin.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3997734     DOI: 10.1152/jappl.1985.58.5.1723

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  5 in total

1.  Vasoactive intestinal peptide in bovine pulmonary artery: localisation, function and receptor autoradiography.

Authors:  P J Barnes; A Cadieux; J R Carstairs; B Greenberg; J M Polak; K Rhoden
Journal:  Br J Pharmacol       Date:  1986-09       Impact factor: 8.739

2.  Adenoviral transfer of vasoactive intestinal peptide (VIP) gene inhibits rat aortic and pulmonary artery smooth muscle cell proliferation.

Authors:  Rose-Claire St Hilaire; Philip J Kadowitz; James R Jeter
Journal:  Peptides       Date:  2009-08-19       Impact factor: 3.750

3.  VIP and endothelin receptor antagonist: an effective combination against experimental pulmonary arterial hypertension.

Authors:  Sayyed A Hamidi; Richard Z Lin; Anthony M Szema; Sergey Lyubsky; Ya Ping Jiang; Sami I Said
Journal:  Respir Res       Date:  2011-10-26

4.  NFATc3 and VIP in Idiopathic Pulmonary Fibrosis and Chronic Obstructive Pulmonary Disease.

Authors:  Anthony M Szema; Edward Forsyth; Benjamin Ying; Sayyed A Hamidi; John J Chen; Sonya Hwang; Jonathan C Li; Debra Sabatini Dwyer; Juan M Ramiro-Diaz; Wieslawa Giermakowska; Laura V Gonzalez Bosc
Journal:  PLoS One       Date:  2017-01-26       Impact factor: 3.240

5.  Vasodilatory effect of the stable vasoactive intestinal peptide analog RO 25-1553 in murine and rat lungs.

Authors:  Jun Yin; Liming Wang; Ning Yin; Arata Tabuchi; Hermann Kuppe; Gerhard Wolff; Wolfgang M Kuebler
Journal:  PLoS One       Date:  2013-09-19       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.